NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.
Read Original Story

$300 to learn risk of prostate cancer

Rating

5 Star

$300 to learn risk of prostate cancer

Our Review Summary

On the whole, this is a well crafted story about a new genetic test that may provide men with advance knowledge about their potential to develop prostate cancer in the future.  The story made it very clear that gaining this information is not without cost above and beyond the test.  This new screen suffers from the same problem as the currently available methods of detecting prostate cancer, namely determining whether the cancer will be deadly or not.  This is a critical piece of information because as the story points out – the treatments for prostate cancer are not without side effect.  It will fall upon the men taking this test who have an indication of high risk to then make a determination of the course of action they want to pursue.  It is important for them to recognize that at this point in time, we do not yet know whether aggressive treatment of early detected prostate cancer is effective.  

The story allowed the test’s promoters to have their say.  But it offered good context and balance, particularly with the quote about the impact on a man’s decision-making, which is key:  “Technology today enables us to find out a huge amount of information,” Dr. Gelmann said. “But how does the public deal with this information? How does it help them make decisions? And if they make a decision, does that lead to a day, a week, a month, of life saved?”

Criteria

Does the story adequately discuss the costs of the intervention?

Satisfactory

The story included a cost for the test.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

The story did provide some discussion on the conundrum presented by prostate cancer detection – namely that it is really an incomplete piece of information. The real goal is to develop a means of distinguishing between indolent and deadly prostate cancer.  The risk of the former would not warrant treatment likely to render the individual impotent and/or incontinent.  The risk of the latter might be worth the risk, or at least participation in active surveillance to allow for detection of a cancer while it is still localized.  The story did mention this conundrum though it might have spent more time on it.

The benefit of this treatment is an early warning of a pathology that might develop; it is less clear what a man in his 30s would do with this information. 

Does the story adequately explain/quantify the harms of the intervention?

Satisfactory

The story did include mention of the harms that are associated with treatment of prostate cancer, namely impotence and incontinence, and that the treatment of prostate cancer may not be at all necessary because not all prostate cancers are life threatening.  As this is a very counter-intuitive thought (that not all cancers are deadly) it might have been emphasized more.

 It is critical that people be aware that while a large clinical trial (the PIVOT study) is underway, it is not yet known whether aggressive treatment of early prostate cancer is effective or whether it may cause more harm than good.  So while the effectiveness of prostate cancer screening remains controversial,it’s important to note that aggressive treatment of early prostate cancer remains controversial too.  

Does the story seem to grasp the quality of the evidence?

Satisfactory

The story was about variant forms of several genes each of which appear to confer some risk for the development of prostate cancer by the time a man reached the age of 65.  It explained that this was a single study and that the contention that these alleles can be put to predictive use needs to be tested in several different populations in order to confirm the contention that they have merit for this use.

Does the story commit disease-mongering?

Satisfactory

A couple of the quotes border on disease-mongering when discussing the prospect of earlier prostate cancer screening – even in men in their 30s.. However, the story attempted to provide some context with expert comment questioning the wisdom in this approach.

Does the story use independent sources and identify conflicts of interest?

Satisfactory

The story included comments from experts in the field who were not connected to the study reported on.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

The story never mentioned that it is an option to decline screening.

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

The story reported that the company that would be offering the test estimated that it would be available in a matter of months.

Does the story establish the true novelty of the approach?

Satisfactory

The story was clear that the genetic screen to predict risk of developing prostate cancer was not yet commercially available.

Does the story appear to rely solely or largely on a news release?

Satisfactory

The story included interview material with several respected clinicians active in this field.

Total Score: 9 of 10 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.